<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01180504</url>
  </required_header>
  <id_info>
    <org_study_id>OVAR-IMRT-02</org_study_id>
    <nct_id>NCT01180504</nct_id>
  </id_info>
  <brief_title>Consolidation Whole Abdominal Intensity-Modulated Radiation Therapy (IMRT) in Advanced Ovarian Cancer</brief_title>
  <acronym>OVAR-IMRT-02</acronym>
  <official_title>Consolidation Intensity-Modulated Whole Abdominal Radiotherapy for High-Risk Patients With Ovarian Cancer Stage FIGO III</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deutsche Krebshilfe e.V., Bonn (Germany)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Heidelberg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this phase-II study is to assess the toxicity of consolidation
      intensity-modulated whole-abdominal radiotherapy using tomotherapy in patients with advanced
      optimally debulked stage International Federation of Gynecology and Obstetrics (FIGO) III
      ovarian cancer with a complete remission after adjuvant chemotherapy.

      36 patients will be treated to a total dose of 30 Gy in 1.5 Gy fractions. The planning
      target-volume includes the entire peritoneal cavity and the pelvic and para-aortal node
      regions. Intensity-modulated whole-abdominal radiotherapy allows an effective sparing of
      liver, kidneys and bone-marrow (vertebral bodies and pelvic bones).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>compatibility of the treatment</measure>
    <time_frame>Beginning of radiotherapy till 6 weeks after its completion</time_frame>
    <description>Therapy compatibility defined as non-occurrence of life-threatening grade 4 (CTCAE v3.0) acute toxicity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of incomplete radiotherapy</measure>
    <time_frame>4 weeks</time_frame>
    <description>Rate of incomplete radiotherapy due to treatment toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of delayed radiotherapy</measure>
    <time_frame>4 weeks</time_frame>
    <description>Rate of delayed radiotherapy due to treatment toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute toxicity</measure>
    <time_frame>From the beginning of radiotherapy till 6 weeks after its completion</time_frame>
    <description>Graded according CTCAE Version 3.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late Toxicity</measure>
    <time_frame>6 weeks -3 years after the completion of radiotherapy</time_frame>
    <description>Graded according CTCAE Version 3.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>3 years after the completion of radiotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>3 years</time_frame>
    <description>assessed using EORTC QLQ-C30 Questionnaire</description>
  </secondary_outcome>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Tubal Carcinoma</condition>
  <condition>Primary Peritoneal Carcinoma</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>intensity-modulated whole-abdominal radiotherapy</intervention_name>
    <description>Consolidation intensity-modulated whole-abdominal radiotherapy using helical tomotherapy to a total dose of 30 Gy in 1.5 Gy fractions</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically confirmed ovarian cancer or tube cancer or primary peritoneal carcinoma
             stage FIGO III

          -  primary optimal debulking surgery

          -  postoperative gross residual tumor â‰¤ 1cm ( R0, R1 oder R2 &lt; 1cm situation)

          -  adjuvant chemotherapy with platin and taxane

          -  complete remission after chemotherapy

          -  Karnofsky performance score &gt; 60

          -  patients &gt;18 years of age

          -  written informed consent

        Exclusion Criteria:

          -  stage FIGO I or II

          -  stage III with postoperative gross residual tumor &gt; 1cm

          -  stage FIGO IV

          -  recurrence situation

          -  delayed wound healing post laparotomy

          -  leucopenia &lt;2000/ml before radiotherapy

          -  thrombocytopenia &lt;75000/ml before radiotherapy

          -  clinically active renal, hepatic, cardiac, metabolic, respiratory, coagulation or
             hematopoietic disease

          -  status post pelvic or abdominal radiotherapy

          -  status post other cancer disease in the past 5 years (cervical cancer in situ, basal
             cell carcinoma, squamous cell carcinoma of the skin are excluded)

          -  participation in another clinical trial
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Schneeweiss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Gyneacology and Obstetrics, Unversity of Heidelberg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juergen Debus, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Radiation Oncology, University of Heidelberg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nathalie Rochet, MD</last_name>
    <phone>0049 6221 56 8202</phone>
    <email>nathalie.rochet@med.uni-heidelberg.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Radiation Oncology, University of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie Rochet, MD</last_name>
      <phone>0049 6221 56 8201</phone>
      <email>nathalie.rochet@med.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Juergen Debus, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Rochet N, Sterzing F, Jensen AD, Dinkel J, Herfarth KK, Schubert K, Eichbaum MH, Schneeweiss A, Sohn C, Debus J, Harms W. Intensity-modulated whole abdominal radiotherapy after surgery and carboplatin/taxane chemotherapy for advanced ovarian cancer: phase I study. Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1382-9. doi: 10.1016/j.ijrobp.2009.03.061. Epub 2009 Jul 21.</citation>
    <PMID>19628341</PMID>
  </reference>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2010</study_first_submitted>
  <study_first_submitted_qc>August 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2010</study_first_posted>
  <last_update_submitted>August 11, 2010</last_update_submitted>
  <last_update_submitted_qc>August 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2010</last_update_posted>
  <responsible_party>
    <name_title>Juergen Debus / Prof., M.D., PhD</name_title>
    <organization>Department of Radiation Oncology, University of Heidelberg</organization>
  </responsible_party>
  <keyword>ovarian cancer</keyword>
  <keyword>whole-abdominal radiotherapy</keyword>
  <keyword>consolidation treatment</keyword>
  <keyword>helical tomotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

